The Role of IL-23 Inhibitors in Crohn's Disease

被引：14

作者：

Fanizza, Jacopo ^{[1
]}

D'Amico, Ferdinando ^{[1
,2
]}

Lusetti, Francesca ^{[1
,3
]}

Fasulo, Ernesto ^{[1
]}

Allocca, Mariangela ^{[1
]}

Furfaro, Federica ^{[1
]}

Zilli, Alessandra ^{[1
]}

Parigi, Tommaso Lorenzo ^{[1
]}

Radice, Simona ^{[1
]}

Peyrin-Biroulet, Laurent ^{[4
,5
,6
,7
,8
,9
]}

Danese, Silvio ^{[1
]}

Fiorino, Gionata ^{[1
,10
]}

机构：

[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Gastroenterol & Endoscopy, I-20132 Milan, Italy

[2] Humanitas Univ, Dept Biomed Sci, I-20089 Milan, Italy

[3] Univ Pavia, Dept Gastroenterol, IRCCS Policlin San Matteo, I-27100 Pavia, Italy

[4] Nancy Univ Hosp, Dept Gastroenterol, F-54500 Vanoeuvre Les Nancy, France

[5] Univ Lorraine, Inserm, NGERE, F-54000 Nancy, France

[6] Nancy Univ Hosp, INFINY Inst, F-54500 Vandoevre Les Nancy, France

[7] Nancy Univ Hosp, FHU CURE, F-54500 Vanoeuvre Les Nancy, France

[8] Paris IBD Ctr, Grp Hosp Pr Ambroise Pare Hartmann, F-92200 Neuilly Sur Seine, France

[9] McGill Univ, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ H4A 3J1, Canada

[10] San Camillo Forlanini Hosp, Dept Gastroenterol & Digest Endoscopy, IBD Unit, I-00152 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 01期

关键词：

inflammatory bowel disease; Crohn's disease; IL-23; inhibitors; risankizumab; guselkumab; mirikizumab; brazikumab; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CYTOKINE; USTEKINUMAB; RISANKIZUMAB; INDUCTION; MODERATE; INTERLEUKIN-12; PROTEIN;

D O I：

10.3390/jcm13010224

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12/23, is currently approved for the treatment of IBD in patients with disease refractory to corticosteroids and biologic drugs. Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD). However, only risankizumab currently has been approved for its treatment. Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.

引用

页数：19

共 76 条

[1]

abbvie, AbbVie's SKYRIZI (Risankizumab) Met All Primary and Secondary Endpoints Versus Stelara (Ustekinumab) in Head-To-Head Study in Crohn's Disease

[2]

accessdata.fda, Skyrizi-Full Prescribing Information

[3] Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation [J].

Aden, Konrad ;

Rehman, Ateequr ;

Falk-Paulsen, Maren ;

Secher, Thomas ;

Kuiper, Jan ;

Tran, Florian ;

Pfeuffer, Steffen ;

Sheibani-Tezerji, Raheleh ;

Breuer, Alexandra ;

Luzius, Anne ;

Jentzsch, Marlene ;

Haesler, Robert ;

Billmann-Born, Susanne ;

Will, Olga ;

Lipinski, Simone ;

Bharti, Richa ;

Adolph, Timon ;

Iovanna, Juan L. ;

Kempster, Sarah L. ;

Blumberg, Richard S. ;

Schreiber, Stefan ;

Becher, Burkhard ;

Chamaillard, Mathias ;

Kaser, Arthur ;

Rosenstiel, Philip .

CELL REPORTS, 2016, 16 (08) :2208-2218

[4] The interleukin-23 axis in intestinal inflammation [J].

Ahern, Philip P. ;

Izcue, Ana ;

Maloy, Kevin J. ;

Powrie, Fiona .

IMMUNOLOGICAL REVIEWS, 2008, 226 :147-159

[5]

An, Active and Placebo-Controlled Study of Brazikumab in Participants with Moderately to Severely Active Crohn's Disease-Full Text View-ClinicalTrials

[6] Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus [J].